Otago Daily Times

WHO recommends use of AstraZenec­a shot


GENEVA: The benefits of the Covid19 vaccine developed by AstraZenec­a and Oxford University outweigh any risks and the shot should recommende­d for use, including in people aged 65 and older and in countries where the South African variant of the virus may reduce its efficacy, a World Health Organisati­on panel said yesterday.

In interim recommenda­tions on the shot, the Strategic Advisory Group of Experts on Immunisati­on (SAGE) panel said the vaccine should be given in two doses, with an interval of about 8 to 12 weeks between the first and second doses.

SAGE also said that even where questions had been raised about the vaccine’s efficacy against a South African variant of Covid19, ‘‘there is no reason not to recommend its use’’.

South Africa this week paused its rollout of the AstraZenec­a vaccine after data from a small trial showed it did not protect against mild to moderate illness from the 501Y.V2 variant of the virus now dominant in the country. — Reuters

 ?? PHOTO: REUTERS ?? The AstraZenec­a vaccine.
PHOTO: REUTERS The AstraZenec­a vaccine.

Newspapers in English

Newspapers from New Zealand